Quarterly Activity Report and 4C Quarterly Cash Flow Report released. Botanix held A$48.36 million cash with no debt, which will fund operations through the transition to a revenue generating pharmaceutical company with full commercial launch of Sofdra™ in Q1 2025. View Report.
The Australian Financial Review has featured Botanix as an ASX favourite.
In an article profiling stock picks by Liam Donohue from Lennox Capital, he assessed the market opportunity for Sofdra™:
‘…current treatments have been more invasive (such as targeted Botox injections) and typically less effective.
‘So, with many of the more binary risks out of the way for Botanix, we think the opportunity in front of the company is immense. That is especially the case when you couple this with management’s history of commercialising pharma products in the US.’
